Keros Therapeutics (KROS) Receivables - Net (2021 - 2025)
Keros Therapeutics' Receivables - Net history spans 4 years, with the latest figure at $3.6 million for Q4 2025.
- For Q4 2025, Receivables - Net rose 30.09% year-over-year to $3.6 million; the TTM value through Dec 2025 reached $3.6 million, up 30.09%, while the annual FY2025 figure was $3.6 million, 30.09% up from the prior year.
- Receivables - Net reached $3.6 million in Q4 2025 per KROS's latest filing, up from $3.5 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $18.0 million in Q4 2021 to a low of $4000.0 in Q2 2024.
- Average Receivables - Net over 4 years is $5.6 million, with a median of $2.7 million recorded in 2024.
- The largest YoY upside for Receivables - Net was 395300.0% in 2025 against a maximum downside of 30.09% in 2025.
- A 4-year view of Receivables - Net shows it stood at $18.0 million in 2021, then plummeted by 99.21% to $143000.0 in 2023, then soared by 1817.48% to $2.7 million in 2024, then surged by 30.09% to $3.6 million in 2025.
- Per Business Quant, the three most recent readings for KROS's Receivables - Net are $3.6 million (Q4 2025), $3.5 million (Q3 2025), and $15.8 million (Q2 2025).